Business
Incannex (ASX:IHL) share price backtracks on FDA update
The Incannex Healthcare Ltd (ASX: IHL) share price is in reverse during late-afternoon trade. This comes despite the company’s positive pre-investigational new drug application (pre-IND) meeting with the United States Food and Drug Administration (FDA).
At the time of writing, the healthcare company’s shares are trading at 28.5 cents, down 1.7%. In comparison, the All Ordinaries Index (ASX: XAO) is 0.4% higher to 7,288 points.
FDA update
According to its release, Incannex announced it received positive feedback from the FDA Pre-IND meeting regarding the regulatory pathway for IHL-675A.
Incannex’s IHL-675A is a novel therapy that comprises hydroxychloroquine (HCQ) and cannabidiol (CBD). The medical therapy is being targeted…
-
Business13 hours agoUp 57% in a year, why this ASX 200 tech stock could keep charging higher into 2026
-
Noosa News8 hours agoTwo people fighting for life as car and caravan crash into creek off Bruce Hwy
-
Noosa News12 hours agoAustralian artist Nara Walker was imprisoned in Iceland — now she’s painting to process her trauma
-
Noosa News13 hours agoBrisbane students given QPS work experience opportunity to remember